<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:30:24Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:2193089" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:2193089</identifier><datestamp>2008-04-16</datestamp><setSpec>jexpmed</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Exp Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">J. Exp. Med</journal-id>
      <journal-title-group>
        <journal-title>The Journal of Experimental Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0022-1007</issn>
      <issn pub-type="epub">1540-9538</issn>
      <publisher>
        <publisher-name>The Rockefeller University Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC2193089</article-id>
      <article-id pub-id-type="pmcid">PMC2193089</article-id>
      <article-id pub-id-type="pmc-uid">2193089</article-id>
      <article-id pub-id-type="pmid">10359588</article-id>
      <article-id pub-id-type="pmid">10359588</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Brief Definitive Reports</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Neutrophil-specific Granule Deficiency Results from a Novel Mutation with Loss of Function of the Transcription Factor CCAAT/Enhancer Binding Protein Îµ </article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lekstrom-Himes</surname>
            <given-names>Julie A.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dorman</surname>
            <given-names>Susan E.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kopar</surname>
            <given-names>Piroska</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Holland</surname>
            <given-names>Steven M.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gallin</surname>
            <given-names>John I.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff id="N0x1a0a190N0x1f2f970">From the Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892</aff>
      <author-notes>
        <fn>
          <p>Address correspondence to John I. Gallin, Bldg. 10, Rm. 2C146, 10 Center Dr. MSC 1504, Bethesda, MD 20892-1504. Phone: 301-496-4114; Fax: 301-402-0244; E-mail: <email>jgallin@cc.nih.gov</email>
</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>7</day>
        <month>6</month>
        <year>1999</year>
      </pub-date>
      <volume>189</volume>
      <issue>11</issue>
      <fpage>1847</fpage>
      <lpage>1852</lpage>
      <history>
        <date date-type="received">
          <day>9</day>
          <month>3</month>
          <year>1999</year>
        </date>
        <date date-type="rev-recd">
          <day>1</day>
          <month>4</month>
          <year>1999</year>
        </date>
      </history>
      <permissions>
        <copyright-year>1999</copyright-year>
        <license license-type="openaccess">
          <license-p>This article is distributed under the terms of an AttributionâNoncommercialâShare AlikeâNo Mirror Sites license for the first six months after the publication date (see <ext-link ext-link-type="uri" xlink:href="http://www.rupress.org/terms">http://www.rupress.org/terms</ext-link>). After six months it is available under a Creative Commons License (AttributionâNoncommercialâShare Alike 4.0 Unported license, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/">http://creativecommons.org/licenses/by-nc-sa/4.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Neutrophil-specific granule deficiency (SGD) is a rare disorder characterized by recurrent pyogenic infections, defective neutrophil chemotaxis and bactericidal activity, and lack of neutrophil secondary granule proteins. CCAAT/enhancer binding protein (C/EBP)Îµ, a member of the leucine zipper family of transcription factors, is expressed primarily in myeloid cells, and its knockout mouse model possesses distinctive defects, including a lack of neutrophil secondary granule proteins. Sequence analysis of the genomic DNA of a patient with SGD revealed a five-basepair deletion in the second exon of the C/EBPÎµ locus. The predicted frame shift results in a truncation of the 32-kD major C/EBPÎµ isoform, with loss of the dimerization domain, DNA binding region, and transcriptional activity. The multiple functional defects observed in these early neutrophil progenitor cells, a consequence of C/EBPÎµ deficiency, define SGD as a defect in myelopoiesis and establish the requirement for C/EBPÎµ for the promyelocyteâmyelocyte transition in myeloid differentiation.</p>
      </abstract>
      <kwd-group>
        <kwd>myelopoiesis</kwd>
        <kwd>lactoferrin</kwd>
        <kwd>granulocyte</kwd>
        <kwd>immunodeficiency</kwd>
        <kwd>neutrophil</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Neutrophil-specific granule deficiency (SGD) is a rare congenital disorder marked by frequent and severe bacterial infections. The five reported cases consistently describe pleiotropic characteristics, including lack of secondary granule proteins and defensins, abnormalities in neutrophil migration and disaggregation, atypical nuclear morphology, and impaired bactericidal activity (<xref rid="B1" ref-type="bibr">1</xref>â<xref rid="B11" ref-type="bibr">11</xref>). More recent work has revealed additional granule abnormalities in the eosinophils of SGD patients, with absence of eosinophil-specific granule contents, including eosinophil cationic protein, eosinophil-derived neurotoxin, and major basic protein (<xref rid="B12" ref-type="bibr">12</xref>). Platelet disorders and associated bleeding diatheses, including the neutrophilic phagocytosis of platelets (<xref rid="B13" ref-type="bibr">13</xref>) and the absence of plateletâhigh-molecular-mass von Willebrand factor multimers stored in platelet Î± granules (<xref rid="B14" ref-type="bibr">14</xref>), have also been reported in SGD patients. In contrast to these seemingly genetically unrelated manifestations, these patients express normal levels of salivary lactoferrin (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>), a characteristic specific granule marker absent in neutrophils in SGD, suggesting that the responsible defect involves myeloid-specific transcriptional regulation.</p>
    <p>CCAAT/enhancer binding proteins (C/EBPs) comprise a family of transcription factors that are key regulators of cellular differentiation and function in a variety of tissues (<xref rid="B17" ref-type="bibr">17</xref>). The prototypic C/EBP is a modular protein consisting of one or more activation domains, a dimerization basic zipper domain and a DNA binding region (<xref rid="B18" ref-type="bibr">18</xref>). C/EBPs are least conserved in their activation domains and vary from dominant negative repressors to strong activators.</p>
    <p>C/EBPÎµ, the newest member of the family, is expressed exclusively in cells of myeloid and T cell lineage (<xref rid="B19" ref-type="bibr">19</xref>â<xref rid="B22" ref-type="bibr">22</xref>). The human C/EBPÎµ gene encodes four mRNA isoforms with varying splice patterns, driven from two alternative promoters, and from which are translated three protein isoforms (<xref rid="B23" ref-type="bibr">23</xref>). Analogous to what has been shown for C/EBPÎ± and C/EBPÎ² (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>), in vitro transfection data suggest that the full length, 32-kD isoform of C/EBPÎµ (C/EBPÎµ<sup>32</sup>) possesses the fully active transcriptional activation domain, whereas the short, 14.2-kD isoform (C/EBPÎµ<sup>14</sup>) lacks transcriptional activity (<xref rid="B23" ref-type="bibr">23</xref>).</p>
    <p>Nearly 60% of C/EBPÎµ knockout mice (<xref rid="B26" ref-type="bibr">26</xref>) succumb to low pathogenicity bacterial infections by 4â6 mo of age. Neutrophils from C/EBPÎµ knockout mice have morphological features similar to human SGD neutrophils, including bilobed nuclei, absent specific and tertiary granule contents, and defective chemotaxis and bactericidal activity (<xref rid="B27" ref-type="bibr">27</xref>). The striking phenotypic similarities between SGD defects and the C/EBPÎµ knockout model prompted a search for a C/EBPÎµ knockout mutation in an SGD patient's genomic locus.</p>
    <sec sec-type="materials|methods">
      <title>Materials and Methods</title>
      <sec disp-level="3">
        <title>Patient.</title>
        <p>Material from a previously described (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>) male patient lacking neutrophil-specific granules was studied. Research was conducted with informed consent under the guidelines of a National Institutes of Health (NIH) Internal Review Boardâ approved protocol, no. 92-I-99. The patient died from complications of pneumonia at age 20.</p>
      </sec>
      <sec disp-level="3">
        <title>DNA, RNA, and Protein Extraction.</title>
        <p>Peripheral blood neutrophils were isolated as described (<xref rid="B28" ref-type="bibr">28</xref>), cryopreserved with dimethylformamide (<named-content content-type="company" xlink:href="sigma">Sigma Chemical Co.</named-content>), and maintained at â140Â°C. Cell proteins were extracted as described (<xref rid="B29" ref-type="bibr">29</xref>). DNA extraction from cryopreserved fibroblasts proceeded as described (<xref rid="B30" ref-type="bibr">30</xref>). RNA was extracted from patient bone marrow aspirate using RNAzol reagent (Teltest) as per manufacturer's protocol. Normal human bone marrow RNA was purchased from <named-content content-type="company" xlink:href="clontech">Clontech</named-content>.</p>
      </sec>
      <sec disp-level="3">
        <title>PCR Amplification of Genomic Sequence.</title>
        <p>PCR reaction was performed using Platinum taq DNA polymerase (Life Technologies) per manufacturer's instructions and cycled as follows: 96Â°C for 12 min, followed by a three-step cycleâ94Â°C for 30 s, 60Â°C for 30 s, and 72Â°C for 2 minâfor 35â40 cycles. PCR products were gel purified and recovered using Gene Clean (Bio101). Products were sequenced with an ABI Prism Dye Terminator Cycle Sequencing Ready Reaction Kit (<named-content content-type="company" xlink:href="perkin">Perkin-Elmer Corp.</named-content>). Primers were chosen from a published sequence available from EMBL/GenBank/DDBJ under accession no. <ext-link ext-link-type="gen" xlink:href="U48865">U48865</ext-link>. Primer sets (upstream, downstream): B, 5â²-AGC GGC CAT GCA AAA GGA AAG ACA, 5â²-TCC ACC TAC CCC CAA GAG AAA GTT (bp 667â1186); C, 5â²-CCC ACG GGA CCT ACT ACG A, 5â²-GGG CTG GCC TGC TCT TAC (bp 1818â2343); F, 5â²-CTC CCC GGC TGG CCC CTT ACA C, 5â²-GCC AAC AGT CCC AAC ACC CAG TCA (bp 3133â3615); G, 5â²-GGA GGT GGG GCT ACA AAA GAA ACT, 5â²-TCA GGG AGG GGC AGG ACA (bp 1143â1553); H, 5â²-ACA GGA GTG GGT GAC AGA GGA GAC, 5â²-GGG CCG AAG GTA TGT GGA GGG TAG (bp 1563â2104); I, 5â²-CCA TGC CCC CTC CTC TTG TTT CTC, 5â²-ACT GCC TTC TTG CCC TTG TGT AA (bp 2594â3171); K, 5â²-AAC TTT CTC TTG GGG GTA GGT GGA, 5â²-TCG TAG TAG GTC CCG TGG (bp 1163â 1837). Homozygosity was determined by hybridization of the PCR product fragment C to a [<sup>32</sup>P]Î³dATP-endlabeled internal oligonucleotide (H. downstream; sequence above). Labeled oligo was mixed with hybridization buffer (75 mM NaCl, 5 mM EDTA) in a ratio of 1:10, and 10 Î¼l was added to 30 Î¼l PCR product. Hybridization was cycled in a thermal cycler: 95Â°C for 5 min and 55Â°C for 10 min. Reactions were immediately placed on ice. Products were resolved on 4â20% Tris/borate/EDTA polyacrylamide gel (Novex) at 250 V.</p>
      </sec>
      <sec disp-level="3">
        <title>RNA Blotting Assay.</title>
        <p>10 Î¼g of total RNA isolated from the patient's bone marrow and 0.25, 0.5, and 1 Î¼g of control polyadenylated (pA)-mRNA was electrophoretically separated, blotted, hybridized, and washed as described (<xref rid="B27" ref-type="bibr">27</xref>). The membrane was stripped by boiling and stored at â20Â°C.</p>
      </sec>
      <sec disp-level="3">
        <title>Immunoblotting.</title>
        <p>Protein quantitation was performed using a BCA Protein Assay kit (<named-content content-type="company" xlink:href="pierce">Pierce Chemical Co.</named-content>) according to the manufacturer's instructions. 10â100 Î¼g protein extracts were electrophoretically separated, transferred to nitrocellulose, and incubated with primary antibody as described (<xref rid="B29" ref-type="bibr">29</xref>). Primary antibody was generated in rabbits by Research Genetics, Inc., using a synthetic peptide encoded in exon 2 of C/EBPÎµ, downstream of the SGD deletion (DPRAVAVKEEPRGPEGSR). The membranes were washed, incubated with antiârabbit horseradish peroxidase conjugate antibody (ECL Western blot kit; <named-content content-type="company" xlink:href="amersham">Amersham</named-content>
<named-content content-type="company" xlink:href="pharmacia">Pharmacia Biotech, Inc.</named-content>), and developed according to the manufacturer's instructions. Membranes were stripped and reblotted with antiâmouse human Î² actin antibody (<named-content content-type="company" xlink:href="boehringer">Boehringer Mannheim</named-content>) to control for protein loading.</p>
      </sec>
      <sec disp-level="3">
        <title>In Vitro Mutagenesis Assay.</title>
        <p>The patient's mutation was introduced into the pCMV-C/EBPÎµ<sup>32</sup> expression vector using a Stratagene QuikChange site-directed mutagenesis kit per manufacturer's instructions using a complementary oligonucleotide (PAGE purified; purchased from Genosys Biotech) containing the deletion (5â²-CCA CTA CTT GCC GCC CTC GGC CCT TTG CCT ACC). Presence of the mutation and maintenance of the vector sequences was verified by sequencing and restriction enzyme digestion, respectively.</p>
      </sec>
      <sec disp-level="3">
        <title>Transient Transfections.</title>
        <p>HeLa cells were maintained in DMEM (BioWhittaker) supplemented with 10% heat-inactivated FBS (Life Technologies, Inc.) and penicillin/streptomycin at 37Â°C and 5% CO<sub>2</sub>. Cells were plated in 6-well plates and transfected within 24 h, at 30â50% confluency. Transfections, using the Mammalian Transfection System (Stratagene), were performed using 5 Î¼g reporter plasmid (G-CSF receptor promoter-luc); 1, 2, or 5 Î¼g inducer plasmid (pCMV-C/EBPÎ±, pCMV-C/EBPÎµ<sup>32</sup> isoform, pCMV-C/EBPÎµ<sup>14</sup> isoform, or pCMV-C/EBPÎµ<sup>32</sup>-SGD, described above); and 0.5 Î¼g pCMVÎ², as described (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B31" ref-type="bibr">31</xref>). The DNA content of transfections was normalized, and transfection was performed according to the manufacturer's instructions, with 300 Î¼l transfection solution applied to the cells. Samples were harvested 24 h after transfection.</p>
        <p>Luciferase and Î²-galactosidase activities were measured using a Dual-Light kit (Tropix, Inc.), according to the manufacturer's protocol, on a Turner 20/20 Luminometer. Samples were read for 15 s after a 3-s delay.</p>
      </sec>
    </sec>
    <sec>
      <title>Results and Discussion</title>
      <p>Sequencing of PCR products from genomic DNA detected a 5-bp deletion, TGACC, in exon 2 of the patient's C/EBPÎµ sequence. Fig. <xref ref-type="fig" rid="F1">1</xref> A shows sequence data from one normal control (top sequence) and the SGD patient (bottom sequence). The mutation predicts a frameshift and a premature termination of the encoded C/EBPÎµ<sup>32</sup> isoform (Fig. <xref ref-type="fig" rid="F1">1</xref> B). The missense code after the frameshift results in the loss of the critical DNA binding domain and leucine zipper region required for C/EBP dimerization and function. C/EBPÎµ transcripts encoding the shorter 27- and 14-kD isoforms are predicted to be unaffected, based upon the splice donor and acceptor and translational start sites (<xref rid="B23" ref-type="bibr">23</xref>). </p>
      <p>Homozygosity of the deletion was determined by PCR amplification of the affected region and resolution of the DNA fragments on a 4â20% polyacrylamide gel (Fig. <xref ref-type="fig" rid="F1">1</xref> C). DNA from one normal control and the SGD patient were mixed before amplification and electrophoresis (lane 3), showing bands from both affected and normal alleles. In comparison, PCR products from the SGD patient (lane 4) and normal controls (lanes 1 and 2) show only one fragment, indicating homozygosity for their respective alleles.</p>
      <p>RNA blot analysis of the SGD patient's bone marrow total RNA showed decreased amounts of C/EBPÎµ transcripts in comparison with control human bone marrow pA-RNA (Fig. <xref ref-type="fig" rid="F2">2</xref> A). Hybridization with a [<sup>32</sup>P]dCTP- labeled actin probe (provided by L. Perera, National Cancer Institute, NIH) showed that 10 Î¼g of SGD patient bone marrow total RNA was equivalent to 1 Î¼g of normal bone marrow pA-mRNA and verified the stability and quality of the patient's RNA preparation. Specific loss of C/EBPÎµ transcripts in the SGD patient is likely due to mRNA instability secondary to the frameshift and the premature termination codon, as seen in other similar gene mutations (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>). Residual C/EBPÎµ message is likely comprised by C/EBPÎµ<sup>14</sup> and C/EBPÎµ<sup>27</sup> transcripts, which are unaffected by the 5-bp deletion and similar in size to the C/EBPÎµ<sup>32</sup> transcript. Transcripts of C/EBPÎ± were present in normal amounts. C/EBPÎ± has a more proximal role in the myelopoietic pathway and specifically induces expression of C/EBPÎµ (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>). As expected, message for lactoferrin was not detected in the SGD patient's bone marrow RNA. </p>
      <p>As predicted from the C/EBPÎµ transcript maps (Fig. <xref ref-type="fig" rid="F1">1</xref> B), immunoblotting detected C/EBPÎµ<sup>27</sup> and C/EBPÎµ<sup>14</sup> isoforms, but not C/EBPÎµ<sup>32</sup>, in neutrophils from the SGD patient (Fig. <xref ref-type="fig" rid="F2">2</xref> B). All three isoforms were seen in the normal control. The antibody used is specific for a peptide sequence immediately downstream of the 5-bp mutation and should not bind the C/EBPÎµ<sup>32</sup>-SGD protein.</p>
      <p>Transient transfection assays in HeLa cells, using the G-CSF receptor promoter driving the luciferase gene (<xref rid="B31" ref-type="bibr">31</xref>), compared the transactivation potentials of the inducer genes C/EBPÎ±, C/EBPÎµ<sup>32</sup>, C/EBPÎµ<sup>14</sup>, and C/EBPÎµ<sup>32</sup>-SGD (Fig. <xref ref-type="fig" rid="F3">3</xref>). C/EBPÎµ<sup>32</sup> has been shown to transactivate the G-CSF receptor promoter, whereas the C/EBPÎµ<sup>14</sup> isoform lacks transactivating function (<xref rid="B23" ref-type="bibr">23</xref>). Transient transfection of these plasmid constructs showed a significant loss of transactivation with the C/EBPÎµ<sup>32</sup>-SGD isoform (<italic>P</italic> = 0.02, Mann-Whitney U test). The demonstrated in vitro data, as well as the in vivo SGD phenotype, mark the full length, 32-kD isoform as the major transactivator encoded in the C/EBPÎµ locus. </p>
      <p>The temporal link between granule protein production and myeloid lineage differentiation is well described: primary granule proteins are synthesized in myeloblasts and promyelocytes, secondary granules are produced in myelocytes and metamyelocytes, and tertiary granule proteins are generated in band and segmented neutrophils (<xref rid="B36" ref-type="bibr">36</xref>).</p>
      <p>Previous work suggested that C/EBPÎµ functions at the terminal stages of myeloid differentiation (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B26" ref-type="bibr">26</xref>). However, the total absence of patient neutrophil secondary granules and the selective loss of primary granule defensins marks an early myelopoietic block at the promyelocyte transition (Fig. <xref ref-type="fig" rid="F4">4</xref>). Further evidence for this conclusion comes from in vitro differentiation experiments using C/EBPÎµ-deficient stem cells, which do not proceed beyond the promyelocyte stage (<xref rid="B26" ref-type="bibr">26</xref>). Other functional defects seen in mouse and human C/EBPÎµ-deficient neutrophils, such as loss of tertiary granule gelatinase (<xref rid="B27" ref-type="bibr">27</xref>) and abnormalities in chemotaxis and cytokine expression (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B27" ref-type="bibr">27</xref>), may occur secondary to the block at the promyelocyte or later stage. </p>
      <p>Functional analysis of the previously developed C/EBPÎµ knockout mouse model (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>) was critical for the interpretation of the C/EBPÎµ mutation in SGD. The apparent multiplicity of C/EBPÎµ target genes at different cell stages suggests that C/EBPÎµ transactivates a set of early cell stageâ specific genes, inducing normal promyelocyte differentiation and granule development. Additional evidence supporting these conclusions comes from recent observations suggesting that C/EBPÎµ is induced by and transduces the G-CSF signal in neutrophils early in myelopoiesis (<xref rid="B37" ref-type="bibr">37</xref>). Absence of secondary granules, defensins, eosinophil cationic protein, eosinophil-derived neurotoxin (<xref rid="B12" ref-type="bibr">12</xref>), and platelet Î± granule high-molecular-mass von Willebrand factor (<xref rid="B14" ref-type="bibr">14</xref>) in SGD demonstrates a critical role for C/EBPÎµ in the development of granules and their contents in multiple myeloid lineages.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>We are grateful to Dr. Helene Rosenberg for providing SGD patient bone marrow RNA and Dr. Mitchell Horwitz for providing normal peripheral blood CD34<sup>+</sup> selected cells and expertise.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spitznagel</surname><given-names>JK</given-names></name><name><surname>Cooper</surname><given-names>MR</given-names></name><name><surname>McCall</surname><given-names>AE</given-names></name><name><surname>DeChatelet</surname><given-names>LR</given-names></name><name><surname>Welsh</surname><given-names>IRH</given-names></name></person-group>
<article-title>Selective deficiency of granules associated with lysozyme and lactoferrin in human polymorphs with reduced microbicidal capacity</article-title>
<source>J Clin Invest</source>
<year>1972</year>
<volume>51</volume>
<fpage>93a</fpage>
<comment>. (Abstr.)</comment>
</element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Strauss</surname><given-names>RG</given-names></name><name><surname>Bove</surname><given-names>KE</given-names></name><name><surname>Jones</surname><given-names>JF</given-names></name><name><surname>Mauer</surname><given-names>AM</given-names></name><name><surname>Fulginiti</surname><given-names>VA</given-names></name></person-group>
<article-title>An anomaly of neutrophil morphology with impaired function</article-title>
<source>N Engl J Med</source>
<year>1974</year>
<volume>290</volume>
<fpage>478</fpage>
<lpage>484</lpage>
<?supplied-pmid 4129798?><pub-id pub-id-type="pmid">4129798</pub-id></element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parmley</surname><given-names>RT</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name><name><surname>Darby</surname><given-names>CP</given-names></name><name><surname>Spicer</surname><given-names>SS</given-names></name></person-group>
<article-title>Congenital neutropenia: neutrophil proliferation with abnormal maturation</article-title>
<source>Blood</source>
<year>1975</year>
<volume>46</volume>
<fpage>723</fpage>
<lpage>734</lpage>
<?supplied-pmid 1174707?><pub-id pub-id-type="pmid">1174707</pub-id></element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Komiyama</surname><given-names>A</given-names></name><name><surname>Morosawa</surname><given-names>H</given-names></name><name><surname>Nakahata</surname><given-names>T</given-names></name><name><surname>Miyagawa</surname><given-names>Y</given-names></name><name><surname>Akabane</surname><given-names>T</given-names></name></person-group>
<article-title>Abnormal neutrophil maturation in a neutrophil defect with morphologic abnormality and impaired function</article-title>
<source>J Pediatr</source>
<year>1979</year>
<volume>94</volume>
<fpage>19</fpage>
<lpage>25</lpage>
<?supplied-pmid 758416?><pub-id pub-id-type="pmid">758416</pub-id></element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Breton-Gorius</surname><given-names>J</given-names></name><name><surname>Mason</surname><given-names>DY</given-names></name><name><surname>Bruiot</surname><given-names>D</given-names></name><name><surname>Vilde</surname><given-names>JL</given-names></name><name><surname>Griscelli</surname><given-names>C</given-names></name></person-group>
<article-title>Lactoferrin deficiency as a consequence of a lack of specific granule in neutrophils from a patient with recurrent infections</article-title>
<source>Am J Pathol</source>
<year>1980</year>
<volume>99</volume>
<fpage>413</fpage>
<lpage>419</lpage>
<?supplied-pmid 6155073?><pub-id pub-id-type="pmid">6155073</pub-id></element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gallin</surname><given-names>JI</given-names></name><name><surname>Fletcher</surname><given-names>MP</given-names></name><name><surname>Seligmann</surname><given-names>BE</given-names></name><name><surname>Hoffstein</surname><given-names>S</given-names></name><name><surname>Cehrs</surname><given-names>K</given-names></name><name><surname>Mounessa</surname><given-names>N</given-names></name></person-group>
<article-title>Human neutrophil-specific granule deficiency: a model to assess the role of neutrophil-specific granules in the evolution of the inflammatory response</article-title>
<source>Blood</source>
<year>1982</year>
<volume>59</volume>
<fpage>1317</fpage>
<lpage>1329</lpage>
<?supplied-pmid 7044447?><pub-id pub-id-type="pmid">7044447</pub-id></element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boxer</surname><given-names>LA</given-names></name><name><surname>Coates</surname><given-names>TD</given-names></name><name><surname>Haak</surname><given-names>RA</given-names></name><name><surname>Wolach</surname><given-names>JB</given-names></name><name><surname>Hoffstein</surname><given-names>S</given-names></name><name><surname>Baehner</surname><given-names>RL</given-names></name></person-group>
<article-title>Lactoferrin deficiency associated with altered granulocyte function</article-title>
<source>N Engl J Med</source>
<year>1982</year>
<volume>307</volume>
<fpage>404</fpage>
<lpage>410</lpage>
<?supplied-pmid 7088114?><pub-id pub-id-type="pmid">7088114</pub-id></element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ambruso</surname><given-names>DR</given-names></name><name><surname>Sasada</surname><given-names>M</given-names></name><name><surname>Nishiyama</surname><given-names>H</given-names></name><name><surname>Kubo</surname><given-names>A</given-names></name><name><surname>Komiyama</surname><given-names>A</given-names></name><name><surname>Allen</surname><given-names>RH</given-names></name></person-group>
<article-title>Defective bactericidal activity and absence of specific granules in neutrophils from a patient with recurrent bacterial infections</article-title>
<source>J Clin Immunol</source>
<year>1984</year>
<volume>4</volume>
<fpage>23</fpage>
<lpage>30</lpage>
<?supplied-pmid 6321538?><pub-id pub-id-type="pmid">6321538</pub-id></element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Borregaard</surname><given-names>N</given-names></name><name><surname>Boxer</surname><given-names>LA</given-names></name><name><surname>Smolen</surname><given-names>JE</given-names></name><name><surname>Tauber</surname><given-names>AI</given-names></name></person-group>
<article-title>Anomolous neutrophil granule distribution in a patient with lactoferrin deficiency</article-title>
<source>Am J Hematol</source>
<year>1985</year>
<volume>18</volume>
<fpage>255</fpage>
<lpage>260</lpage>
<?supplied-pmid 2983535?><pub-id pub-id-type="pmid">2983535</pub-id></element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ganz</surname><given-names>T</given-names></name><name><surname>Metcalf</surname><given-names>JA</given-names></name><name><surname>Gallin</surname><given-names>JI</given-names></name><name><surname>Boxer</surname><given-names>LA</given-names></name><name><surname>Lehrer</surname><given-names>RI</given-names></name></person-group>
<article-title>Microbicidal/cytotoxic proteins of neutrophils are deficient in two disorders: Chediak-Higashi Syndrome and âspecificâ granule deficiency</article-title>
<source>J Clin Invest</source>
<year>1988</year>
<volume>82</volume>
<fpage>552</fpage>
<lpage>556</lpage>
<?supplied-pmid 2841356?><pub-id pub-id-type="pmid">2841356</pub-id></element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tamura</surname><given-names>A</given-names></name><name><surname>Agematsu</surname><given-names>K</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Kawai</surname><given-names>H</given-names></name><name><surname>Kuratsuji</surname><given-names>T</given-names></name><name><surname>Shimane</surname><given-names>M</given-names></name><name><surname>Tani</surname><given-names>K</given-names></name><name><surname>Asano</surname><given-names>S</given-names></name><name><surname>Komiyama</surname><given-names>A</given-names></name></person-group>
<article-title>A marked decrease in defensin mRNA in the only case of congenital neutrophil-specific granule deficiency reported in Japan</article-title>
<source>Int J Hematol</source>
<year>1994</year>
<volume>59</volume>
<fpage>137</fpage>
<lpage>142</lpage>
<?supplied-pmid 8018907?><pub-id pub-id-type="pmid">8018907</pub-id></element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>HF</given-names></name><name><surname>Gallin</surname><given-names>JI</given-names></name></person-group>
<article-title>Neutrophil-specific granule deficiency includes eosinophils</article-title>
<source>Blood</source>
<year>1993</year>
<volume>82</volume>
<fpage>268</fpage>
<lpage>273</lpage>
<?supplied-pmid 8324226?><pub-id pub-id-type="pmid">8324226</pub-id></element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sakura</surname><given-names>T</given-names></name><name><surname>Murakami</surname><given-names>H</given-names></name><name><surname>Matsushima</surname><given-names>T</given-names></name><name><surname>Tamura</surname><given-names>J</given-names></name><name><surname>Sawamura</surname><given-names>M</given-names></name><name><surname>Tsuchiya</surname><given-names>J</given-names></name></person-group>
<article-title>Ultrastructure of neutrophilic phagosome of autologous platelet in vivo in specific granule deficiency</article-title>
<source>Am J Hematol</source>
<year>1993</year>
<volume>43</volume>
<fpage>149</fpage>
<lpage>150</lpage>
<?supplied-pmid 8342544?><pub-id pub-id-type="pmid">8342544</pub-id></element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parker</surname><given-names>RI</given-names></name><name><surname>McKeown</surname><given-names>LP</given-names></name><name><surname>Gallin</surname><given-names>JI</given-names></name><name><surname>Gralnick</surname><given-names>HR</given-names></name></person-group>
<article-title>Absence of the largest platelet-von Willebrand multimers in a patient with lactoferrin deficiency and a bleeding tendency</article-title>
<source>Thromb Haemost</source>
<year>1992</year>
<volume>67</volume>
<fpage>320</fpage>
<lpage>324</lpage>
<?supplied-pmid 1641822?><pub-id pub-id-type="pmid">1641822</pub-id></element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lomax</surname><given-names>KJ</given-names></name><name><surname>Gallin</surname><given-names>JI</given-names></name><name><surname>Rotrosen</surname><given-names>D</given-names></name><name><surname>Raphael</surname><given-names>GD</given-names></name><name><surname>Kaliner</surname><given-names>MA</given-names></name><name><surname>Benz</surname><given-names>EJ</given-names></name><name><surname>Boxer</surname><given-names>LA</given-names></name><name><surname>Malech</surname><given-names>HL</given-names></name></person-group>
<article-title>Selective defect in myeloid cell lactoferrin gene expression in neutrophil-specific granule deficiency</article-title>
<source>J Clin Invest</source>
<year>1989</year>
<volume>83</volume>
<fpage>514</fpage>
<lpage>519</lpage>
<?supplied-pmid 2536400?><pub-id pub-id-type="pmid">2536400</pub-id></element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Raphael</surname><given-names>GD</given-names></name><name><surname>Davis</surname><given-names>JL</given-names></name><name><surname>Fox</surname><given-names>PC</given-names></name><name><surname>Malech</surname><given-names>HL</given-names></name><name><surname>Gallin</surname><given-names>JI</given-names></name><name><surname>Baraniuk</surname><given-names>JN</given-names></name><name><surname>Kaliner</surname><given-names>MA</given-names></name></person-group>
<article-title>Glandular secretion of lactoferrin in a patient with neutrophil lactoferrin deficiency</article-title>
<source>J Allergy Clin Immunol</source>
<year>1989</year>
<volume>84</volume>
<fpage>914</fpage>
<lpage>919</lpage>
<?supplied-pmid 2600325?><pub-id pub-id-type="pmid">2600325</pub-id></element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lekstrom-Himes</surname><given-names>JA</given-names></name><name><surname>Xanthopoulos</surname><given-names>KG</given-names></name></person-group>
<article-title>Biological role of the CCAAT/enhancer-binding protein family of transcription factors</article-title>
<source>J Biol Chem</source>
<year>1998</year>
<volume>273</volume>
<fpage>28545</fpage>
<lpage>28548</lpage>
<?supplied-pmid 9786841?><pub-id pub-id-type="pmid">9786841</pub-id></element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Williams</surname><given-names>SC</given-names></name><name><surname>Cantwell</surname><given-names>CA</given-names></name><name><surname>Johnson</surname><given-names>PF</given-names></name></person-group>
<article-title>A family of C/EBP-related proteins capable of forming covalently linked leucine zipper dimers in vitro</article-title>
<source>Genes Dev</source>
<year>1991</year>
<volume>5</volume>
<fpage>1553</fpage>
<lpage>1567</lpage>
<?supplied-pmid 1884998?><pub-id pub-id-type="pmid">1884998</pub-id></element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Antonson</surname><given-names>P</given-names></name><name><surname>Stellan</surname><given-names>B</given-names></name><name><surname>Yamanaka</surname><given-names>R</given-names></name><name><surname>Xanthopoulos</surname><given-names>KG</given-names></name></person-group>
<article-title>A novel human CCAAT/enhancer binding protein gene, C/EBPÎµ, is expressed in cells of lymphoid and myeloid lineages and is localized on chromosome 14q11.2 close to the T-cell receptor Î±/Î´ locus</article-title>
<source>Genomics</source>
<year>1996</year>
<volume>35</volume>
<fpage>30</fpage>
<lpage>38</lpage>
<?supplied-pmid 8661101?><pub-id pub-id-type="pmid">8661101</pub-id></element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chumakov</surname><given-names>AM</given-names></name><name><surname>Grillier</surname><given-names>I</given-names></name><name><surname>Chumakova</surname><given-names>E</given-names></name><name><surname>Chih</surname><given-names>D</given-names></name><name><surname>Slater</surname><given-names>J</given-names></name><name><surname>Koeffler</surname><given-names>HP</given-names></name></person-group>
<article-title>Cloning of the novel human myeloid-cell-specific C/EBPÎµ transcription factor</article-title>
<source>Mol Cell Biol</source>
<year>1997</year>
<volume>17</volume>
<fpage>1375</fpage>
<lpage>1386</lpage>
<?supplied-pmid 9032264?><pub-id pub-id-type="pmid">9032264</pub-id></element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koike</surname><given-names>M</given-names></name><name><surname>Chumakov</surname><given-names>AM</given-names></name><name><surname>Takeuchi</surname><given-names>S</given-names></name><name><surname>Tasaka</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Nakamaki</surname><given-names>T</given-names></name><name><surname>Tsuruoka</surname><given-names>N</given-names></name><name><surname>Koeffler</surname><given-names>HP</given-names></name></person-group>
<article-title>C/EBP-Îµ: chromosomal mapping and mutational analysis of the gene in leukemia and preleukemia</article-title>
<source>Leuk Res</source>
<year>1997</year>
<volume>21</volume>
<fpage>833</fpage>
<lpage>839</lpage>
<?supplied-pmid 9393598?><pub-id pub-id-type="pmid">9393598</pub-id></element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Williams</surname><given-names>SC</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Schwartz</surname><given-names>RC</given-names></name><name><surname>Weiler</surname><given-names>SR</given-names></name><name><surname>Ortiz</surname><given-names>M</given-names></name><name><surname>Keller</surname><given-names>JR</given-names></name><name><surname>Johnson</surname><given-names>PF</given-names></name></person-group>
<article-title>C/EBPÎµ is a myeloid-specific activator of cytokine, chemokine and macrophage-colony-stimulating factor receptor genes</article-title>
<source>J Biol Chem</source>
<year>1998</year>
<volume>22</volume>
<fpage>13493</fpage>
<lpage>13501</lpage>
<?supplied-pmid 9593684?><pub-id pub-id-type="pmid">9593684</pub-id></element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yamanaka</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>G-D</given-names></name><name><surname>Rodomska</surname><given-names>HS</given-names></name><name><surname>Lekstrom-Himes</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>LT</given-names></name><name><surname>Antonson</surname><given-names>P</given-names></name><name><surname>Tenen</surname><given-names>DG</given-names></name><name><surname>Xanthopoulos</surname><given-names>KG</given-names></name></person-group>
<article-title>CCAAT/enhancer binding protein Îµ is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>1997</year>
<volume>94</volume>
<fpage>6462</fpage>
<lpage>6467</lpage>
<?supplied-pmid 9177240?><pub-id pub-id-type="pmid">9177240</pub-id></element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ossipow</surname><given-names>V</given-names></name><name><surname>Descombes</surname><given-names>P</given-names></name><name><surname>Schibler</surname><given-names>U</given-names></name></person-group>
<article-title>CCAAT/enhancer-binding protein mRNA is translated into multiple proteins with different transcription activation potentials</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>1993</year>
<volume>90</volume>
<fpage>8219</fpage>
<lpage>8223</lpage>
<?supplied-pmid 8367486?><pub-id pub-id-type="pmid">8367486</pub-id></element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Descombes</surname><given-names>P</given-names></name><name><surname>Schibler</surname><given-names>U</given-names></name></person-group>
<article-title>A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA</article-title>
<source>Cell</source>
<year>1991</year>
<volume>67</volume>
<fpage>569</fpage>
<lpage>579</lpage>
<?supplied-pmid 1934061?><pub-id pub-id-type="pmid">1934061</pub-id></element-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yamanaka</surname><given-names>R</given-names></name><name><surname>Barlow</surname><given-names>C</given-names></name><name><surname>Lekstrom-Himes</surname><given-names>J</given-names></name><name><surname>Castilia</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Eckhaus</surname><given-names>M</given-names></name><name><surname>Decker</surname><given-names>T</given-names></name><name><surname>Wynshaw-Boris</surname><given-names>A</given-names></name><name><surname>Xanthopoulos</surname><given-names>KG</given-names></name></person-group>
<article-title>Impaired granulopoiesis, myelodysplasia, and early lethality in C/EBPÎµ deficient mice</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>1997</year>
<volume>94</volume>
<fpage>13187</fpage>
<lpage>13192</lpage>
<?supplied-pmid 9371821?><pub-id pub-id-type="pmid">9371821</pub-id></element-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lekstrom-Himes</surname><given-names>JA</given-names></name><name><surname>Xanthopoulos</surname><given-names>KG</given-names></name></person-group>
<article-title>C/EBPÎµ is critical for effective neutrophil-mediated response to inflammatory challenge</article-title>
<source>Blood</source>
<year>1999</year>
<volume>93</volume>
<fpage>3096</fpage>
<lpage>3105</lpage>
<?supplied-pmid 10216107?><pub-id pub-id-type="pmid">10216107</pub-id></element-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuhns</surname><given-names>DB</given-names></name><name><surname>Young</surname><given-names>HA</given-names></name><name><surname>Gallin</surname><given-names>EK</given-names></name><name><surname>Gallin</surname><given-names>JI</given-names></name></person-group>
<article-title>Ca<sup>2+</sup>-dependent production and release of IL-8 in human neutrophils</article-title>
<source>J Immunol</source>
<year>1998</year>
<volume>161</volume>
<fpage>4332</fpage>
<lpage>4339</lpage>
<?supplied-pmid 9780210?><pub-id pub-id-type="pmid">9780210</pub-id></element-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dorman</surname><given-names>SE</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name></person-group>
<article-title>Mutation in the signal-transducing chain of the interferon Î³ receptor and susceptibility to mycobacterial infection</article-title>
<source>J Clin Invest</source>
<year>1998</year>
<volume>101</volume>
<fpage>2364</fpage>
<lpage>2369</lpage>
<?supplied-pmid 9616207?><pub-id pub-id-type="pmid">9616207</pub-id></element-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Laird</surname><given-names>PW</given-names></name><name><surname>Zijderveld</surname><given-names>A</given-names></name><name><surname>Linders</surname><given-names>K</given-names></name><name><surname>Rudnicki</surname><given-names>MA</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name><name><surname>Berns</surname><given-names>A</given-names></name></person-group>
<article-title>Simplified mammalian DNA isolation procedure</article-title>
<source>Nucleic Acids Res</source>
<year>1991</year>
<volume>19</volume>
<fpage>4293</fpage>
<?supplied-pmid 1870982?><pub-id pub-id-type="pmid">1870982</pub-id></element-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>LT</given-names></name><name><surname>Hohaus</surname><given-names>S</given-names></name><name><surname>Gonzalez</surname><given-names>DA</given-names></name><name><surname>Dziennis</surname><given-names>SE</given-names></name><name><surname>Tenen</surname><given-names>DG</given-names></name></person-group>
<article-title>PU.1 (Spi-1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells</article-title>
<source>Blood</source>
<year>1996</year>
<volume>88</volume>
<fpage>1234</fpage>
<lpage>1247</lpage>
<?supplied-pmid 8695841?><pub-id pub-id-type="pmid">8695841</pub-id></element-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hovnanian</surname><given-names>A</given-names></name><name><surname>Rochat</surname><given-names>A</given-names></name><name><surname>Bodemer</surname><given-names>C</given-names></name><name><surname>Petit</surname><given-names>E</given-names></name><name><surname>Rivers</surname><given-names>CA</given-names></name><name><surname>Prost</surname><given-names>C</given-names></name><name><surname>Fraitag</surname><given-names>S</given-names></name><name><surname>Christiano</surname><given-names>AM</given-names></name><name><surname>Uitto</surname><given-names>J</given-names></name><name><surname>Lathrop</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Characterization of 18 new mutations in COL7A1 in recessive dystrophic epidermolysis bullosa provides evidence for distinct molecular mechanisms underlying defective anchoring fibril formation</article-title>
<source>Am J Hum Genet</source>
<year>1997</year>
<volume>61</volume>
<fpage>599</fpage>
<lpage>610</lpage>
<?supplied-pmid 9326325?><pub-id pub-id-type="pmid">9326325</pub-id></element-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Christiano</surname><given-names>AM</given-names></name><name><surname>Amano</surname><given-names>S</given-names></name><name><surname>Eichenfield</surname><given-names>LF</given-names></name><name><surname>Burgeson</surname><given-names>RE</given-names></name><name><surname>Uitto</surname><given-names>J</given-names></name></person-group>
<article-title>Premature termination codon mutations in the type VII collagen gene in recessive dystrophic epidermolysis bullosa result in nonsense-mediated mRNA decay and absence of functional protein</article-title>
<source>J Invest Dermatol</source>
<year>1997</year>
<volume>109</volume>
<fpage>390</fpage>
<lpage>394</lpage>
<?supplied-pmid 9284110?><pub-id pub-id-type="pmid">9284110</pub-id></element-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D-E</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>N-D</given-names></name><name><surname>Hetherington</surname><given-names>CJ</given-names></name><name><surname>Darlington</surname><given-names>GJ</given-names></name><name><surname>Tenen</surname><given-names>DG</given-names></name></person-group>
<article-title>Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>1997</year>
<volume>94</volume>
<fpage>569</fpage>
<lpage>574</lpage>
<?supplied-pmid 9012825?><pub-id pub-id-type="pmid">9012825</pub-id></element-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Radomska</surname><given-names>HS</given-names></name><name><surname>Huettner</surname><given-names>CS</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>T</given-names></name><name><surname>Scadden</surname><given-names>DT</given-names></name><name><surname>Tenen</surname><given-names>DG</given-names></name></person-group>
<article-title>CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors</article-title>
<source>Mol Cell Biol</source>
<year>1998</year>
<volume>18</volume>
<fpage>4301</fpage>
<lpage>4314</lpage>
<?supplied-pmid 9632814?><pub-id pub-id-type="pmid">9632814</pub-id></element-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Borregaard</surname><given-names>N</given-names></name><name><surname>Sehested</surname><given-names>M</given-names></name><name><surname>Nielsen</surname><given-names>BS</given-names></name><name><surname>Sengelov</surname><given-names>H</given-names></name><name><surname>Kjeldsen</surname><given-names>L</given-names></name></person-group>
<article-title>Biosynthesis of granule proteins in normal human bone marrow cells. Gelatinase is a marker of terminal neutrophil differentiation</article-title>
<source>Blood</source>
<year>1995</year>
<volume>85</volume>
<fpage>812</fpage>
<lpage>817</lpage>
<?supplied-pmid 7833481?><pub-id pub-id-type="pmid">7833481</pub-id></element-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>H</given-names></name><name><surname>Cleveland</surname><given-names>JL</given-names></name><name><surname>Nagata</surname><given-names>S</given-names></name><name><surname>Ihle</surname><given-names>JN</given-names></name></person-group>
<article-title>Granulocyte colony-stimulating factor regulates myeloid differentiation through CCAAT enhancer binding protein Îµ</article-title>
<source>Blood</source>
<year>1998</year>
<volume>92</volume>
<fpage>712a</fpage>
<?supplied-pmid 9680338?><pub-id pub-id-type="pmid">9680338</pub-id></element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>(A) Sequence data from PCR products of normal control genomic DNA (top) and SGD patient DNA (bottom). Sequencing was performed on three separate PCRs from the SGD patient and three normal controls. Color coding of nucleotides on sequence scan is red, T; green, A; black, G; blue, C. Underlined nucleotides, 5-bp deletion. Arrowhead, location of deletion in the SGD patient sequence. Schematic drawing of C/EBPÎµ locus shows three exons; two alternative promoters, PÎ± and PÎ²; translational start codons; and bZIP region. (B) Schematic drawing of the three human C/EBPÎµ protein isoforms. Second drawing (from top) shows the C/EBPÎµ<sup>32</sup>-SGD isoform with predicted missense region and premature termination codon occurring after the arrowhead. (C) PCR products after liquid hybridization of DNA region containing 5-bp deletion. Lanes 1 and 2, normal controls. Lane 4, patient DNA. Lane 3, PCR products from normal control DNA mixed equimolar with patient DNA. Arrowheads indicate normal allele (top) and SGD allele (bottom). Over 30 normal controls were tested.</p>
      </caption>
      <graphic xlink:href="JEM990414.f1a"/>
      <graphic xlink:href="JEM990414.f1b"/>
      <graphic xlink:href="JEM990414.f1c"/>
    </fig>
    <fig id="F2" position="float">
      <label>Figure 2</label>
      <caption>
        <p>(A) RNA blot of SGD patient bone marrow total RNA and normal human bone marrow pA-RNA. Three concentrations of control RNA, 1, 0.5, and 0.25 Î¼g, and 10 Î¼g of SGD patient RNA were used, as indicated below the lanes. Blot was probed with [<sup>32</sup>P]dCTP-labeled probes, as indicated, and stripped between hybridizations. (B) Immunoblotting of cellular proteins extracted from peripheral blood neutrophils isolated as described. Top panel was blotted with rabbit antiâhuman polyclonal C/EBPÎµ antibody. Center panel was blotted with rabbit antiârat C/EBPârelated protein 1 (<named-content content-type="company" xlink:href="sbct">Santa Cruz Biotechnology</named-content>). Bottom panel shows immunoblotting with mouse antiâhuman actin antibody. Arrowheads indicate C/EBPÎµ<sup>32</sup>, C/EBPÎµ<sup>27</sup>, and C/EBPÎµ<sup>14</sup> isoforms.</p>
      </caption>
      <graphic xlink:href="JEM990414.f2a"/>
      <graphic xlink:href="JEM990414.f2b"/>
    </fig>
    <fig id="F3" position="float">
      <label>Figure 3</label>
      <caption>
        <p>Transcriptional activation of normal C/EBPÎµ and C/EBPÎµ<sup>32</sup>-SGD. Transient transfections in HeLa cells were performed as described. Concentrations of labeled inducer plasmids (pCMV-C/EBPÎ±, pCMV- C/EBPÎµ<sup>32</sup> isoform, pCMV-C/ EBPÎµ<sup>14</sup> isoform, and pCMV-C/ EBPÎµ<sup>32</sup>-SGD) and reporter plasmid, G-CSF receptor promoter-luc, are given (Î¼g). Sample activity was adjusted based on transfection efficiency, measured by Î²-galactosidase activity. Fold increase in luciferase activity was calculated from reporter-only baseline. Data shown represent the mean (dot) and SE (box) of four independent experiments. Significant decreases in luciferase activity were observed between the pCMV-C/EBPÎµ<sup>32</sup> and pCMV-C/EBPÎµ<sup>32</sup>-SGD isoforms (<italic>P</italic> = 0.02, Mann-Whitney U test.)</p>
      </caption>
      <graphic xlink:href="JEM990414.f3"/>
    </fig>
    <fig id="F4" position="float">
      <label>Figure 4</label>
      <caption>
        <p>Neutrophil granule expression during myelopoiesis and abnormalities in neutrophil-specific granule deficiency (broken arrows). The contents of primary granules, with the exception of defensins, are present in SGD neutrophils; however, secondary and tertiary granules are absent. G-CSF induces C/EBPÎµ early in myelopoiesis, which initiates transcription of granule components as indicated.</p>
      </caption>
      <graphic xlink:href="JEM990414.f4"/>
    </fig>
  </floats-group>
</article>

</metadata></record></GetRecord></OAI-PMH>